Clin Exp Vaccine Res.  2014 Jan;3(1):1-4. 10.7774/cevr.2014.3.1.1.

Towards Vaccine 3.0: new era opened in vaccine research and industry

• Rhee JH

• KMID: 2049090
• DOI: http://doi.org/10.7774/cevr.2014.3.1.1

Abstract

No abstract available.

Reference

1. Rappuoli R. From Pasteur to genomics: progress and challenges in infectious diseases. Nat Med. 2004; 10:1177–1185.

2. Bagnoli F, Baudner B, Mishra RP, et al. Designing the next generation of vaccines for global public health. OMICS. 2011; 15:545–566.

3. Poland GA, Jacobson RM. The clinician's guide to the anti-vaccinationists' galaxy. Hum Immunol. 2012; 73:859–866.

4. Greco M. Development and supply of vaccines: an industry perspective. In : Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF, editors. New generation vaccines. 4th ed. New York: Marcel Dekker;2004. p. 75–87.

5. Donati C, Rappuoli R. Reverse vaccinology in the 21st century: improvements over the original design. Ann N Y Acad Sci. 2013; 1285:115–132.

6. Dorrington MG, Bowdish DM. Immunosenescence and novel vaccination strategies for the elderly. Front Immunol. 2013; 4:171.

7. Rhee JH, Lee SE, Kim SY. Mucosal vaccine adjuvants update. Clin Exp Vaccine Res. 2012; 1:50–63.